Mechanisms of resistance to chemoterapeutic and antiangiogenic drugs as novel targets for pancreatic cancer therapy

Starting date
January 1, 2011
Duration (months)
Managers or local contacts
Melisi Davide
pancreatic cancer, treatment resistance, angiogenesis


A.I.R.C. Associazione Italiana per la Ricerca sul Cancro
Funds: assigned and managed by the department

Project participants

Title Authors Year
NF-κB as a target for pancreatic cancer therapy. Carbone, C.; Melisi, Davide 2012
Pancreatic Cancer: between bench and bedside. Melisi, Davide; A., Budillon 2012
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Carbone, C.; Moccia, T.; Zhu, C.; Paradiso, G.; Budillon, A.; Chiao, P. J.; Abbruzzese, J. L.; Melisi, Davide 2011
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. Vaccaro, V; Melisi, Davide; Bria, Emilio; Cuppone, F; Ciuffreda, L; Pino, Ms; Gelibter, A; Tortora, Giampaolo; Cognetti, F; Milella, M. 2011
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. Melisi, Davide; Xia, Q.; Paradiso, G.; Ling, J.; Moccia, T.; Carbone, C.; Budillon, A.; Abbruzzese, J. L.; Chiao, P. J. 2011


Research facilities